InMed details ATM prospectus under new shelf
InMed Pharmaceuticals Inc. filed a prospectus supplement and related prospectus on April 3, 2026 for the sale of its common shares under an existing At The Market Offering Agreement with H.C.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
InMed Pharmaceuticals Inc. filed a prospectus supplement and related prospectus on April 3, 2026 for the sale of its common shares under an existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC. These potential sales are made pursuant to a shelf registration statement on Form S-3, which was filed on March 20, 2026 and declared effective on March 30, 2026.
The company also filed a legal opinion from Norton Rose Fulbright Canada LLP as Exhibit 5.1 covering the legality of the common shares issuable under the Sales Agreement and included a related consent as Exhibit 23.1.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
ATM Agreement date: April 7, 2022
ATM amendment date: June 27, 2024
Prospectus supplement filing date: April 3, 2026
+3 more
6 metrics
ATM Agreement date
April 7, 2022
Original At The Market Offering Agreement with H.C. Wainwright & Co., LLC
ATM amendment date
June 27, 2024
Amendment to the At The Market Offering Agreement
Prospectus supplement filing date
April 3, 2026
Date InMed filed the prospectus supplement and related prospectus
Shelf registration filing date
March 20, 2026
Form S-3 shelf registration statement filing date
Shelf effectiveness date
March 30, 2026
Date the Form S-3 registration statement was declared effective
Registration file number
File No. 333-294503
SEC file number for InMed’s Form S-3 shelf registration statement
Key Terms
At The Market Offering Agreement, shelf registration statement, Form S-3, prospectus supplement, +2 more
6 terms
At The Market Offering Agreement financial
"entered into an At The Market Offering Agreement dated April 7, 2022"
An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.
shelf registration statement regulatory
"pursuant to the Company’s shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
Form S-3 regulatory
"shelf registration statement on Form S-3 (File No. 333-294503)"
Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.
prospectus supplement financial
"filed a prospectus supplement and related prospectus related to the sale"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did InMed Pharmaceuticals (INM) announce in this 8-K filing?
InMed Pharmaceuticals reported filing a prospectus supplement for potential sales of common shares under its existing At The Market Offering Agreement. These sales are made pursuant to a Form S-3 shelf registration statement that was filed in March 2026 and recently declared effective.
What is the At The Market Offering Agreement mentioned by InMed (INM)?
The At The Market Offering Agreement is an arrangement dated April 7, 2022, as amended June 27, 2024, between InMed Pharmaceuticals and H.C. Wainwright & Co., LLC. It permits the company to sell common shares into the market from time to time through the agent.
How does InMed’s new prospectus supplement relate to its Form S-3 shelf?
The prospectus supplement and related prospectus cover sales of InMed’s common shares under the At The Market Offering Agreement pursuant to its Form S-3 shelf registration statement. That shelf was filed on March 20, 2026 and declared effective by the SEC on March 30, 2026.
Which legal opinion did InMed (INM) file with this 8-K?
InMed filed a legal opinion from Norton Rose Fulbright Canada LLP as Exhibit 5.1. The opinion addresses the legality of the common shares issuable under the Sales Agreement and covered by the prospectus supplement and related prospectus under the effective Form S-3 registration statement.
Who is the sales agent for InMed’s at-the-market program?
H.C. Wainwright & Co., LLC serves as the sales agent for InMed’s At The Market Offering Agreement. Under this agreement, InMed may sell common shares from time to time, with the April 3, 2026 prospectus supplement governing such sales under the company’s effective Form S-3 shelf.
What exhibits did InMed Pharmaceuticals include with this 8-K?
InMed included three exhibits: a Norton Rose Fulbright Canada LLP legal opinion on the legality of the securities as Exhibit 5.1, a related consent as Exhibit 23.1, and a Cover Page Interactive Data File embedded within the Inline XBRL document as Exhibit 104 to support electronic reporting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
